UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2 Journal article
Bioorganic and Medicinal Chemistry, 2009,Volume: 17,Issue: 2,Page: 731-740
Authors:  Duncton M.A.J.;  Piatnitski Chekler E.L.;  Katoch-Rouse R.;  Sherman D.;  Wong W.C.;  Smith II L.M.;  Kawakami J.K.;  Kiselyov A.S.;  Milligan D.L.;  Balagtas C.;  Hadari Y.R.;  Wang Y.;  Patel S.N.;  Rolster R.L.;  Tonra J.R.;  Surguladze D.;  Mitelman S.;  Kussie P.;  Bohlen P.;  Doody J.F.
Favorite  |  View/Download:2/0  |  Submit date:2019/01/16
Angiogenesis  Arylphthalazine  Inhibitor  KDR  Kinase  Phthalazine  VEGFR-2  
Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines Journal article
Bioorganic and Medicinal Chemistry Letters, 2006,Volume: 16,Issue: 5,Page: 1191-1196
Authors:  Ouyang X.;  Piatnitski E.L.;  Pattaropong V.;  Chen X.;  He H.-Y.;  Kiselyov A.S.;  Velankar A.;  Kawakami J.;  Labelle M.;  Smith II L.;  Lohman J.;  Lee S.P.;  Malikzay A.;  Fleming J.;  Gerlak J.;  Wang Y.;  Rosler R.L.;  Zhou K.;  Mitelman S.;  Camara M.;  Surguladze D.;  Doody J.F.;  Tuma M.C.
Favorite  |  View/Download:1/0  |  Submit date:2019/01/16
1,3,4-Oxadiazole  Antimitotic agent  Multiple-drug resistance  Tubulin polymerization inhibitor